Pemvidutide Protocol: Complete Cycling & Dosing Guide

Pemvidutide Protocol: Complete Cycling & Dosing Guide

Overview

Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist peptide developed for metabolic dysfunction and liver health optimization. Unlike single-mechanism compounds, pemvidutide simultaneously activates GLP-1 receptors for appetite suppression and improved glucose control while activating glucagon receptors to increase hepatic fat oxidation and thermogenesis. This dual action produces stronger fat loss effects with preferential preservation of lean mass compared to GLP-1 monotherapy.

Important Disclaimer: Pemvidutide is an investigational compound not approved by the FDA or major regulatory agencies. Its use outside of clinical trials carries significant regulatory and safety uncertainty. This protocol guide is educational content only and should not be construed as medical advice. Consult with a qualified healthcare provider before initiating any peptide protocol.

Standard Protocol Overview

Dosing Range: 1.2–2.4 mg once weekly via subcutaneous injection
Typical Cycle Length: 12–24 weeks continuous
Rest Period: Not typically required; trials used continuous dosing
Administration Route: Subcutaneous injection (abdomen, thigh, or upper arm)
Frequency: Once weekly on the same day each week

The standard protocol follows the dosing evidence from clinical trials. Most practitioners begin at the lowest effective dose and escalate over 4 weeks to minimize gastrointestinal side effects, which are dose-dependent and transient.

Standard Protocol: Dose Escalation Schedule

Weeks 1–4: Initiation Phase

• Dose: 0.6 mg once weekly
• Purpose: Tolerance assessment and GI system adaptation
• Expected effects: Mild appetite suppression, possible mild nausea
• Monitoring: Track side effects daily; note any vomiting or severe nausea

Weeks 5–8: Escalation Phase

• Dose: 1.2 mg once weekly
• Purpose: Increase efficacy while managing adaptation
• Expected effects: Moderate appetite suppression, early satiety, potential loose stools
• Duration: Maintain 4 weeks minimum before further escalation

Weeks 9–12: Therapeutic Phase

• Dose: 1.8 mg once weekly
• Purpose: Achieve maximal fat loss and liver fat reduction
• Expected effects: Strong appetite suppression, consistent weight loss trajectory
• Duration: This dose produces 68.5% reduction in liver fat in clinical populations

Weeks 13+: Maintenance Phase

• Dose: 1.8–2.4 mg once weekly based on tolerance and goals
• Purpose: Sustain fat loss and metabolic improvements
• Adjustment: Increase to 2.4 mg only if well-tolerated and additional fat loss desired

Goal-Specific Protocols

Protocol A: Maximal Fat Loss (12-Week Acute Phase)

This protocol prioritizes rapid body composition change for individuals with 20+ lbs to lose.

• Weeks 1–3: 0.6 mg weekly
• Weeks 4–6: 1.2 mg weekly
• Weeks 7–12: 1.8 mg weekly
• Expected outcome: 4.3% body weight reduction (based on clinical trial data)
• Timeline: Maximum fat loss occurs weeks 8–12
• Post-cycle: Transition to maintenance at 1.8 mg weekly or discontinue with taper

Protocol B: Liver Health Optimization (16-Week MASH Protocol)

This protocol targets hepatic steatosis and metabolic dysfunction-associated steatohepatitis.

• Weeks 1–4: 0.6 mg weekly
• Weeks 5–8: 1.2 mg weekly
• Weeks 9–16: 1.8 mg weekly
• Expected outcome: 68.5% reduction in liver fat; 94.4% achieve ≥30% fat reduction
• Monitoring: Consider liver imaging at baseline, week 8, and week 16
• Metabolic markers: HbA1c, fasting glucose, ALT/AST at baseline and week 16
• Post-protocol: Maintenance dosing 1.8 mg weekly for 8 additional weeks

Protocol C: Conservative/Tolerance-First (24-Week Extended)

For individuals with prior GI sensitivity or those prioritizing adherence over speed.

• Weeks 1–4: 0.6 mg weekly
• Weeks 5–12: 1.2 mg weekly
• Weeks 13–24: 1.8 mg weekly
• Expected outcome: Steady fat loss with minimal nausea; cumulative 4%+ body weight reduction
• Benefits: Longest adaptation period reduces dropout from side effects
• GI management: More time for gut habituation to appetite suppression

Protocol D: Maximum Efficacy (Extended High-Dose)

For experienced practitioners seeking maximal metabolic change.

• Weeks 1–2: 0.6 mg weekly
• Weeks 3–4: 1.2 mg weekly
• Weeks 5–20: 1.8 mg weekly
• Weeks 21–24: 2.4 mg weekly (only if well-tolerated)
• Duration: 24 weeks continuous
• Expected outcome: Cumulative effects of sustained high-dose; enhanced liver fat reduction and thermogenesis
• Monitoring: Weekly side effect assessment weeks 19–24 during high-dose escalation

How to Administer Step-by-Step

Preparation (Before Injection)

1. Reconstitution (if lyophilized powder):

   • Remove vial from refrigeration 15 minutes before use
   • Wipe rubber septum with alcohol swab; let dry 30 seconds
   • Draw bacteriostatic water or saline (volume per product insert) into syringe
   • Inject water into vial slowly; do not shake vigorously
   • Gently swirl vial for 30 seconds until powder dissolves completely
   • Allow 5 minutes for full reconstitution

2. If using pre-filled pen or solution:

   • Remove from refrigeration 15–30 minutes before injection
   • Inspect solution: should be clear and colorless; do not use if cloudy or discolored
   • Check expiration date

3. Dose Preparation:

   • If drawing from vial, attach new needle to insulin syringe
   • Invert vial; draw plunger back to match dose volume
   • Pierce rubber septum at center; inject air equal to dose volume
   • Withdraw dose slowly; inspect syringe for air bubbles
   • Replace needle with fresh injection needle before administering

Administration

1. Site Selection:

   • Rotate between: abdominal area (2 inches from navel), outer thigh, or upper arm
   • Use different injection site each week to prevent lipohypertrophy
   • Avoid areas with active injection site reactions, bruising, or induration
   • Abdomen typically produces fastest absorption; thigh is second-fastest

2. Injection Technique:

   • Cleanse skin with alcohol swab; allow to air dry (critical to prevent stinging)
   • Pinch skin fold between thumb and forefinger
   • Insert needle at 45–90 degree angle into pinched tissue
   • Depress plunger slowly and steadily over 5–10 seconds
   • Hold needle in place 5 seconds after plunger fully depressed
   • Withdraw needle and release skin; apply light pressure with gauze if needed
   • Do not massage injection site

3. Post-Injection:

   • Dispose of needle in sharps container immediately
   • Apply adhesive bandage if desired
   • Note injection site, date, and time in protocol log

Storage and Stability

• Unopened vials/pens: Refrigerate 2–8°C (36–46°F); protect from light
• After reconstitution: Refrigerate at 2–8°C; stable 28 days
• Do not freeze: If accidentally frozen, discard immediately
• Room temperature: Do not leave unrefrigerated for more than 2 hours
• Travel: Use insulated pen case with ice pack or gel packs for transport

Week-by-Week Cycle Example: 12-Week Maximal Fat Loss Protocol

| Week | Dose | Injection Day | Expected Side Effects | Weight Loss Trajectory | Notes |

|------|------|---|---|---|---| | 1 | 0.6 mg | Monday | Mild nausea possible | —0.5% | Tolerance assessment week | | 2 | 0.6 mg | Monday | Minimal to mild nausea | —0.8% | Appetite suppression begins | | 3 | 0.6 mg | Monday | Nausea resolving | —1.0% | Adaptation underway | | 4 | 0.6 mg | Monday | Minimal nausea | —1.2% | Ready for escalation | | 5 | 1.2 mg | Monday | Mild nausea returns | —1.5% | Escalation week; expect temporary increase in GI effects | | 6 | 1.2 mg | Monday | Nausea mild; appetite suppressed | —2.0% | Strong appetite suppression evident | | 7 | 1.2 mg | Monday | Minimal nausea; diarrhea possible | —2.4% | GI symptoms normalizing | | 8 | 1.2 mg | Monday | Minimal GI effects | —2.8% | Therapeutic dose established | | 9 | 1.8 mg | Monday | Mild nausea possible; transient | —3.2% | Peak efficacy dose; maximum fat loss begins | | 10 | 1.8 mg | Monday | Minimal to no nausea | —3.7% | Maximal fat loss window | | 11 | 1.8 mg | Monday | Minimal GI effects | —4.0% | Cumulative effects peak | | 12 | 1.8 mg | Monday | None to minimal | —4.3% | Trial endpoint; sustained weight loss achieved |

Week-by-week notes:

• Weeks 1–4 are tolerance building; weight loss is secondary to adaptation
• Weeks 5–8 show linear weight loss progression; GI symptoms should trend toward resolution
• Weeks 9–12 demonstrate maximal efficacy; expect plateau at 4.3% for most users
• Continue monitoring weight weekly; if plateau occurs, maintain dose rather than increasing

What to Expect: Timeline of Effects

Days 1–3 (Immediate Post-Injection)

• Mild to moderate nausea possible
• Early appetite suppression (20–30% reduction)
• Increased thirst
• Slight fatigue (transient)

Days 4–7 (Peak Efficacy Window)

• Nausea resolves in most users
• Strong appetite suppression (40–60% reduction)
• Reduced cravings for high-calorie foods
• Early satiety at normal meal portions
• Possible loose stools or mild diarrhea
• Injection site erythema (mild, self-resolving in 2–4 days)

Weeks 2–4 (Escalation Window)

• GI symptoms normalize
• Appetite suppression becomes consistent
• Weight loss 0.5–1.5 lbs weekly
• Energy levels stabilize
• Sleep may be deeper or more restful
• Digestive system adapts fully

Weeks 5–8 (Linear Fat Loss Phase)

• Weight loss accelerates to 1–2 lbs weekly
• Appetite suppression is reliable and predictable
• Minimal side effects
• Improved insulin sensitivity (measure via fasting glucose)
• Improved satiety control; portion sizes naturally reduced

Weeks 9–12 (Maximal Efficacy Phase)

• Peak weight loss trajectory (2–3 lbs weekly possible)
• Fat loss preferentially from visceral and hepatic stores
• Muscle mass largely preserved due to glucagon component
• Liver fat reduction 68.5% at 1.8 mg dose
• Metabolic rate elevation from thermogenesis
• Sustained appetite suppression without habituation

Weeks 13+ (Maintenance/Plateau Phase)

• Weight loss velocity slows to 0.5–1 lb weekly
• Body composition stabilizes
• Appetite suppression remains robust
• Sustained metabolic improvements
• Continued liver fat reduction if baseline steatosis present

Signs It's Working

By Week 4:

• Reduced appetite at habitual meal times
• Increased ease in portion control without hunger
• Early satiety on 50% of normal portion sizes

By Week 8:

• Cumulative weight loss of 2–2.8%
• Improved fasting glucose (5–10 mg/dL reduction typical)
• Clothing fit noticeably different (belt notches tighter)

By Week 12:

• Weight loss of 4–4.3% achieved
• Liver imaging shows fat reduction (if baseline steatosis was present)
• Improved metabolic markers: HbA1c, fasting insulin, lipids
• Sustained appetite suppression without nausea

Physical markers:

• Reduction in abdominal circumference
• Improved energy for activity
• Better glycemic control if diabetic
• Reduced water retention

When to Adjust Dosing

Increase dose if:

• After 2 weeks at current dose, appetite suppression is minimal (<20% reduction)
• Weight loss plateau for 3+ weeks at same dose with good adherence
• No GI side effects experienced for 7+ consecutive days at current dose
• Already at week 8+ of protocol and tolerating well

Maintain current dose if:

• Experiencing consistent appetite suppression (30–50% reduction)
• Weight loss is 0.5–2 lbs weekly
• GI side effects are manageable and not limiting quality of life
• On accelerated protocol and only at week 4–6

Reduce or discontinue if:

• Severe vomiting (more than 2–3 episodes per day) lasting beyond day 2 post-injection
• Unmanageable diarrhea (>5 episodes daily) impacting daily function
• Persistent injection site reactions (edema, severe erythema)
• Unexpected adverse reaction (respiratory distress, severe abdominal pain)

Common Protocol Mistakes

Mistake 1: Escalating Too Quickly

• Problem: Jumping from 0.6 to 1.8 mg in week 3 causes severe nausea; users discontinue
• Solution: Strict adherence to 4-week escalation minimum between dose increases
• Prevention: Follow escalation schedule exactly; do not accelerate even if side effects are minimal

Mistake 2: Reconstitution Errors

• Problem: Shaking vial vigorously causes peptide denaturation; reduced efficacy
• Solution: Gently swirl vial; never shake
• Prevention: Use slow rotational motion; allow full 5 minutes for reconstitution

Mistake 3: Inconsistent Injection Day

• Problem: Injecting Monday one week, Thursday the next; missed steady-state hormonal levels
• Solution: Use same day each week; set phone reminder
• Prevention: Calendar or pill organizer with injection schedule

Mistake 4: Underestimating GI Side Effect Duration

• Problem: Expecting nausea to resolve in 24 hours; actually peaks 12–36 hours post-injection
• Solution: Plan first 48 hours post-injection for reduced appetite and potential mild nausea
• Prevention: Inject on Friday or day before lighter schedule; eat anti-nausea ginger or mint

Mistake 5: Not Rotating Injection Sites

• Problem: Using same abdominal location weekly; lipohypertrophy develops by week 6
• Solution: Rotate between at least 4 injection sites per month
• Prevention: Use diagram of body with labeled rotation sites; checkmark each use

Mistake 6: Stopping Abruptly Without Taper

• Problem: Discontinuing at 2.4 mg cold turkey; rebound appetite and potential metabolic shift
• Solution: Taper over 4 weeks if discontinuing after 12+ weeks
• Prevention: Plan end date 4 weeks prior; reduce by 0.6 mg every 2 weeks

How to Stack with Other Compounds

Pemvidutide + Testosterone (TRT Dose)

• Rationale: Testosterone preserves lean mass during caloric deficit; pemvidutide maximizes fat loss
• Dosing: Maintain standard TRT protocol (100–200 mg/week); initiate pemvidutide as per standard protocol
• Monitoring: Lipid panel every 8 weeks; hemoglobin/hematocrit every 12 weeks
• Synergy: Enhanced body recom